New CEO for Janssen Greece
Συγγραφέας iator Γράφτηκε στις ,
Janssen Greece has appointed a new CEO as of 16th November 2015. Efthymios (Makis) Papataxiarchis succeeded Nikos Kefalas, who moved to Janssen Russia as a Managing Director of Janssen Russia and CIS countries.
Makis Papataxiarchis has 20 years of experience in the pharmaceutical industry. He joined Janssen-Cilag Greece in 2000, where he held the positions of the Business Unit Director, and Marketing & Sales Director. In 2010 he moved to the position of Managing Director for Janssen Romania. During his tenure in Romania he was President of the local Association of Pharmaceutical Companies (ARPIM). From 2013 he held the position of National Director, Systems of Care for Janssen Pharmaceuticals Inc. USA. He holds a Pharmacy degree from the University of Patras, MSc and PhD in Pharmaceutical and Economics, as well an MBA in Marketing Management.
Makis Papataxiarchis said: “It is my great pleasure to return to my country and even in a familiar organization. It is surely a great responsibility taking over this position within the current economic circumstances, but it is important that Janssen and Johnson & Johnson are showing full confidence in our country. The priority for the company is the continued sustainable development of the Greek market. The focus of our activities is primarily the patients and of course the provision of innovative pharmaceutical products, aiming to restore health, prolong life and improve its quality, by creating added value for society and for our company. “
Makis Papataxiarchis will report to Bart van Zijl Langhout, Managing Director Janssen Mid-Sized Markets who also said: “Throughout the course of his career, Makis has demonstrated a strong leadership profile with an excellent track record of achieving results and building strong teams. The diverse and rich professional experience made him perfectly suitable for the role of CEO Janssen Greece. “
About Janssen
Janssen belongs to Johnson & Johnson group of companies, and is oriented in providing innovative and high quality products aiming at improving human lives. With main concern the pharmaceutical research, it discovers, develops and markets innovative drugs in five major therapeutic areas: 1. Cardiovascular and metabolic diseases (diabetes), 2. Neuroscience (schizophrenia, dementia, pain), 3. Infectious diseases (HIV / AIDS, Hepatitis C, tuberculosis), 4. Oncology (multiple myeloma, prostate cancer), and 5. Immunology (psoriasis, psoriatic arthritis)
